SER (Serina Therapeutics Inc) Nilai Agregat Aset

Serina Therapeutics, Inc. (SER) laboratories are consistently working on developing brain treatments, yet the lack of sales and dependence on the POZ platform create significant risks in the event of test failures. This chart of total asset quotes is fixed at 19.55. Investor confidence is bolstered by the leadership's authority and the transparency of the patent portfolio, ensuring the high-quality development of the biotech business.

Aset Agregat Perusahaan serinatherapeutics.com (SER): kanggo periode 28.03.2024 - 01.11.2026

Rincian metrik keuangan lan pasar Serina (SER)

- rega saiki lan proyeksi nilai saham:

Bagan kutipan serinatherapeutics.com|SER - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Nilai pasar Serina Pharma|SER - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Serina Therapeutics|SER - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku serinatherapeutics.com|SER - Aset Agregat Perusahaan

- indikator beban utang lan likuiditas:

Rasio Total Utang marang Ekuitas Serina Therapeutics, Inc.|SER - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Serina Pharma|SER - Gunggung utang perusahaan|Rasio utang marang aset resik Serina Pharma|SER - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Serina Therapeutics|Likuiditas darurat serinatherapeutics.com

- rincian bathi lan kelipatan pasar:

SER - Penghasilan resik

Ringkesan analisis perusahaan:serinatherapeutics.com (SER)

The dynamics of total assets and liabilities, calculated reverse-engineered via ROA, serve as a key indicator of financial stability and the scale of the enterprise's resources. By analyzing the total assets of Serina Therapeutics, Inc. (SER) on the GURU.Markets platform, an investor assesses the ability of Serina Therapeutics, Inc. (SER) to fund preclinical research in the absence of commercial revenue, making this chart a primary measure of the biotech startup's viability.

Pesaing utama